Aronora
biopharmaceuticals
Home
Welcome to Aronora
Business Area
Aronora, LLC is a unique biotech start-up company focusing on fundamentally new biological blood clot treatment drugs that do not cause bleeding.
Our product pipeline includes the following two novel drug candidates:
WE-thrombin-is a proprietary injectable thrombus-specific antithrombotic agent – a selective protein C activator enzyme. The recombinant double-mutant human thrombin analog contains two amino acid substitutions: Trp215Ala and Glu217Ala. WE-thrombin is intended for profibrinolytic, neuroprotective, and antithrombotic treatment of patients with acute stroke. The primary advantage of using WE-thrombin in place of tPA for the treatment of ischemic stroke is better safety. The only competing product, tPA, has not gained wide market acceptance, primarily due to its bleeding side effects. WE-thrombin will be evaluated both as a stand-alone treatment and as an add-on therapy to tPA. (WE for stroke video)
AXIMAB-is an anti-factor XI monoclonal antibody. AXIMAB is specific for thrombosis because it inhibits blood coagulation inside blood vessels without measurable effect on the coagulation of blood in wounds. A single dose of AXIMAB anticoagulates primates for more than a week. Inhibition of factor XI has more potent antithrombotic effects than high dose heparin or aspirin, but it has no measurable bleeding side effects. AXIMAB is being developed for use in severe sepsis-associated coagulopathy and for venous thrombosis. (AXIMAB article in Blood)
